Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02553733
Other study ID # 00003242
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date December 2015
Est. completion date December 2024

Study information

Verified date April 2023
Source Penn State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study the investigators will test the hypothesis that short-term consumption of inorganic nitrate (supplied in concentrated beetroot juice) enhances coronary blood flow responses, large artery hemodynamics, and leg oxygenation/exercise tolerance in patients with peripheral arterial disease (PAD). Understanding and improving blood flow regulation in the heart and skeletal muscles of patients with PAD is important because exercise triggers symptoms of leg pain and substantially raises blood pressure and myocardial demand in these patients.


Description:

Peripheral arterial disease (PAD) is a strong predictor of cardiovascular mortality and negatively affects functional capacity and quality of life for as many as 14 million patients in the U.S. alone. One open-label study showed that acute consumption of beetroot juice improved 6 min walk performance, reduced blood pressure, and enhanced leg muscle oxygenation in PAD patients. However, no studies have rigorously confirmed these findings in a double-blind manner, nor have the effects of this supplement been investigated (acutely or short-term) in the coronary circulation of PAD patients. In addition to studying its effects on graded treadmill walking performance and consequent large artery vasodilation, the present study will examine the effects of short-term beetroot juice consumption (twice/day) on both coronary and leg vasodilator (graded calf flexion) and vasoconstrictor (isometric handgrip, voluntary apnea) responses in patients with PAD. Participants will randomly consume either nitrate-rich or nitrate-depleted beetroot juice with a 7 to 14 day wash-out period between. Effects of beetroot juice consumption on plasma nitrate, nitrite and methemoglobin will also be assessed.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 12
Est. completion date December 2024
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 21 Years to 85 Years
Eligibility Inclusion Criteria: 1. Patients with peripheral arterial disease (PAD) 2. Capable of giving informed consent 3. Men and women age 21- 85 years 4. Diagnosed with PAD (i.e., ankle-brachial index below 0.9) 5. Fontaine stage II or less - no pain while resting 6. Satisfactory history and physical exam Exclusion Criteria: 1. Children 2. Pregnant or nursing women 3. Patients taking nitroglycerine or nitrate preparations 4. Patients taking phosphodiesterase inhibitors such as sildenafil or tadalafil 5. Patients taking proton pump inhibitors 6. Ejection fraction < 40% 7. Uncontrolled hypertension 8. Uncontrolled diabetes 9. Myocardial infarction within past 6 months or unstable angina 10. Severe lung disease (i.e., on supplemental oxygen or frequently use rescue inhalers) 11. Abnormality in hemoglobin or hematocrit or methemoglobin 12. Impaired renal function 13. Impaired liver function 14. History or diagnosis of Barrett's esophagus 15. Known allergy to beetroot juice or lemon juice 16. Inability to walk on a treadmill at a moderate pace (2.0 miles/hour)

Study Design


Intervention

Drug:
Beetroot juice
This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
Beetroot juice placebo
This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).

Locations

Country Name City State
United States Milton S. Hershey Medical Center Hershey Pennsylvania

Sponsors (3)

Lead Sponsor Collaborator
David N. Proctor, PhD Milton S. Hershey Medical Center, Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Blood measures of nitrate absorption and conversion Venous blood will be withdrawn (venipuncture) for determination of plasma nitrate, nitrite and methemoglobin levels 4 to 7 days after initiating ingestion of beetroot juice
Primary Exercise performance Exercise capacity will be assessed using a graded treadmill walking test to peak exertion with expired gas analysis and determination of peak oxygen uptake, calf muscle oxygenation, blood pressure, claudication onset time, and peak walking time. 5 to 7 days after initiating daily ingestion of beetroot juice
Secondary Coronary vascular function Coronary artery (transthoracic ultrasound) blood flow responses to plantar flexion and handgrip exercise. 4 days after initiating daily ingestion of beetroot juice
Secondary Leg vascular function Popliteal artery and near infrared spectroscopy (NIRS) responses to plantar flexion and handgrip exercise. 4 days after initiating daily ingestion of beetroot juice
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Completed NCT02384980 - Saving Life and Limb: FES for the Elderly With PAD Phase 1